Cardiovascular risks of antiretroviral therapies.
The use of highly active antiretroviral therapy (HAART) has resulted in sustained reductions in mortality from HIV infection. In recent years, HAART has also been associated with metabolic complications that may increase patients' cardiovascular disease risk. Recent studies have begun to support a more complex interaction between HAART, HIV infection itself, and other traditional social and immunologic factors that may predispose patients to premature cardiovascular disease. Substantial progress has been made in the development of newer antiretroviral therapies that have a better metabolic profile with respect to dyslipidemia, hyperglycemia, and lipodystrophy. Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term.
Mondy
Kristin
K
Washington University School of Medicine, Saint Louis, Missouri 63110, USA. kmondy@im.wustl.edu
Tebas
Pablo
P
D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000494:pharmacology; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D001786:Blood Glucose / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects
D044966:Anti-Retroviral Agents; D001786:Blood Glucose